Connor Clark & Lunn Investment Management Ltd. Acquires 18,095 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 30.1% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 78,244 shares of the biotechnology company’s stock after purchasing an additional 18,095 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Sarepta Therapeutics were worth $9,772,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of SRPT. Innealta Capital LLC purchased a new stake in Sarepta Therapeutics during the second quarter worth $31,000. New Covenant Trust Company N.A. bought a new position in shares of Sarepta Therapeutics in the 1st quarter worth $32,000. Huntington National Bank lifted its stake in shares of Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 175 shares during the last quarter. Nkcfo LLC bought a new stake in Sarepta Therapeutics during the second quarter valued at about $43,000. Finally, Riggs Asset Managment Co. Inc. grew its stake in Sarepta Therapeutics by 33.3% in the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 75 shares during the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SRPT has been the topic of a number of recent analyst reports. Royal Bank of Canada restated an “outperform” rating and issued a $182.00 price target on shares of Sarepta Therapeutics in a report on Monday, October 21st. Guggenheim lifted their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Cantor Fitzgerald upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $152.00 to $167.00 in a report on Thursday, November 7th. Piper Sandler lowered their price objective on Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $205.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $181.33.

Insider Activity

In related news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This represents a 14.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Price Performance

NASDAQ:SRPT opened at $110.50 on Friday. The firm’s fifty day moving average is $122.21 and its two-hundred day moving average is $131.71. The firm has a market cap of $10.55 billion, a price-to-earnings ratio of 88.40 and a beta of 0.81. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics, Inc. has a one year low of $78.67 and a one year high of $173.25.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.